These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 27580190)

  • 41. Development and process evaluation of an educational intervention for overdose prevention and naloxone distribution by general practice trainees.
    Klimas J; Egan M; Tobin H; Coleman N; Bury G
    BMC Med Educ; 2015 Nov; 15():206. PubMed ID: 26590066
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Acceptability and feasibility of naloxone prescribing in primary care settings: A systematic review.
    Behar E; Bagnulo R; Coffin PO
    Prev Med; 2018 Sep; 114():79-87. PubMed ID: 29908763
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Impact of training for healthcare professionals on how to manage an opioid overdose with naloxone: effective, but dissemination is challenging.
    Mayet S; Manning V; Williams A; Loaring J; Strang J
    Int J Drug Policy; 2011 Jan; 22(1):9-15. PubMed ID: 21044832
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Naloxone's role in the national opioid crisis-past struggles, current efforts, and future opportunities.
    Bennett AS; Elliott L
    Transl Res; 2021 Aug; 234():43-57. PubMed ID: 33684591
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Police Officers Can Safely and Effectively Administer Intranasal Naloxone.
    Fisher R; O'Donnell D; Ray B; Rusyniak D
    Prehosp Emerg Care; 2016; 20(6):675-680. PubMed ID: 27218446
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Legal regimes surrounding naloxone access: considerations for prescribers.
    Brodrick JE; Brodrick CK; Adinoff B
    Am J Drug Alcohol Abuse; 2016 Mar; 42(2):117-28. PubMed ID: 26809471
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Barriers to implementation of opioid overdose prevention programs in Ohio.
    Winstanley EL; Clark A; Feinberg J; Wilder CM
    Subst Abus; 2016; 37(1):42-6. PubMed ID: 26682929
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Working together: Expanding the availability of naloxone for peer administration to prevent opioid overdose deaths in the Australian Capital Territory and beyond.
    Lenton S; Dietze P; Olsen A; Wiggins N; McDonald D; Fowlie C
    Drug Alcohol Rev; 2015 Jul; 34(4):404-11. PubMed ID: 25272281
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The implementation of a naloxone rescue program in university students.
    Panther SG; Bray BS; White JR
    J Am Pharm Assoc (2003); 2017; 57(2S):S107-S112.e2. PubMed ID: 28063773
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Naloxone Administration for Opioid Overdose Reversal in the Prehospital Setting: Implications for Pharmacists.
    Weaver L; Palombi L; Bastianelli KMS
    J Pharm Pract; 2018 Feb; 31(1):91-98. PubMed ID: 28399697
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Public attitudes and beliefs about Virginia community pharmacists dispensing and administering naloxone.
    Haggerty LC; Gatewood SS; Goode JKR
    J Am Pharm Assoc (2003); 2018; 58(4S):S73-S77.e1. PubMed ID: 30006189
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Distribution of naloxone for overdose prevention to chronic pain patients.
    Coe MA; Walsh SL
    Prev Med; 2015 Nov; 80():41-3. PubMed ID: 26024850
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Managing Opioid Use in Orthopaedic Patients Through Harm Reduction Strategies.
    Worley J
    Orthop Nurs; 2019; 38(2):129-135. PubMed ID: 30865064
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Quality Assessment Errors and Study Misclassification Threaten Systematic Review Validity: Community Opioid Overdose Prevention and Naloxone Distribution Programs Review: Re: Clark AK, Wilder CM, Winstanley EL. A systematic review of community opioid overdose prevention and naloxone distribution programs. J Addict Med 2014 May-June;8(3): 153-163.
    Orkin AM; Bingham K; Buick JE; Klaiman M; Leece P; Kouyoumdjian F
    J Addict Med; 2015; 9(6):502-3. PubMed ID: 26517325
    [No Abstract]   [Full Text] [Related]  

  • 55. Establishment of a pharmacist-led service for patients at high risk for opioid overdose.
    Tewell R; Edgerton L; Kyle E
    Am J Health Syst Pharm; 2018 Mar; 75(6):376-383. PubMed ID: 29523534
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Naloxone for Opioid Overdose and the Role of the Pharmacist.
    Toderika Y; Williams S
    Consult Pharm; 2018 Feb; 33(2):98-104. PubMed ID: 29409576
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Expanding Access to Naloxone: A Necessary Step to Curb the Opioid Epidemic.
    Houser R
    Disaster Med Public Health Prep; 2022 Sep; 17():e245. PubMed ID: 36172901
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Implementing take-home naloxone in an urban community pharmacy.
    Akers JL; Hansen RN; Oftebro RD
    J Am Pharm Assoc (2003); 2017; 57(2S):S161-S167. PubMed ID: 28202384
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Take-Home Naloxone Program Implementation: Lessons Learned From Seven Chicago-Area Hospitals.
    Eswaran V; Allen KC; Bottari DC; Splawski JA; Bains S; Aks SE; Swoboda HD; Moore PQ; Tran TH; Salisbury-Afshar E; Lank PM; McCarthy DM; Kim HS
    Ann Emerg Med; 2020 Sep; 76(3):318-327. PubMed ID: 32241746
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Opioid overdose prevention training with naloxone, an adjunct to basic life support training for first-year medical students.
    Berland N; Fox A; Tofighi B; Hanley K
    Subst Abus; 2017; 38(2):123-128. PubMed ID: 28027016
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.